CliffBio
small molecule

TOPIRAMATE

TOPIRAMATE

Loss of exclusivity—loss of exclusivity
CompanyXIAMEN LP PHARMACUETICAL CO LTD

Drug detail

Brand nameTOPIRAMATE
Active ingredientTOPIRAMATE
Strength100MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusRX

More from XIAMEN LP PHARMACUETICAL CO LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TOPIRAMATE patent cliff — loss of exclusivity — | CliffBio